Project Grant R01AI184074
Award Date 9/25/25
Completion Date 8/31/29
Dollars Obligated $4.7M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), is funding research to define and model the HIV-1-specific antibody function in HIV-1-exposed infants who were passively infused with broadly neutralizing antibodies in the IMPAACT P1112 trial. The $273,424 award, which runs from April 9, 2025 to March 31, 2027, aims to evaluate the ability of the serum from...
- This federal Project Grant award of $4,630,686 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop an effective HIV vaccine. The primary goal is to stimulate B cell lineages capable of producing broadly neutralizing antibodies (bnAbs) against diverse HIV strains, a key challenge in traditional vaccine approaches. The research involves preclinical studies in non-human primates using the BG505...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $214,996 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Oregon Health & Science University to conduct research titled "Targeting TFH Differentiation to Increase the Magnitude and Durability of Antibody Responses in Infant Rhesus Macaques After SHIV Infection." The research aims to improve HIV- and vaccine-specific antibody development in children living with...
- This federal Project Grant award for $477,406.00, awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research), will fund research to verify the use of pigs as an appropriate model for developing human vaccines that target the entero-mammary pathway to elicit a robust secretory IgA (sIgA) immune response in human milk. The research aims to understand the critical role of sIgA in protecting mucosal surfaces, including in breastfed...
- This $197,366 Project Grant was awarded on March 1, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project aims to identify the molecular mechanisms that control the natural, immune-mediated restriction of X4-tropic HIV virus, which typically emerges only in late-stage HIV disease when the immune system is impaired. The research will utilize primary CD4 T cells, in vivo analyses in...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,379,954 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The grant, awarded on August 21, 2025, supports research to engineer durable immunity by optimizing HIV vaccine parameters to drive long-lived plasma cell development. The project aims to systematically study the effects of immunogen affinity, valency, adjuvants, vaccine platforms, and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,275,484 Cooperative Agreement to Weill Medical College of Cornell University on August 12, 2025 under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The goal of this project is to identify an optimal prime-boost immunization strategy to guide antibody maturation towards broad neutralization of HIV in early life. The project aims to: 1) Compare sequential versus simultaneous...
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $1,285,304 to the Scripps Research Institute to conduct research on developing a durable broadly neutralizing antibody (bnAb) response for an HIV vaccine. The key objectives are to: Assess the durability of a 6-shot sequential vaccine regimen that induces bnAb responses in non-human primates. Evaluate the...
- This federal Project Grant award in the amount of $850,491.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Icahn School of Medicine at Mount Sinai. The grant supports a research project to conduct an in-depth characterization of myeloid cells in human milk from both HIV-positive and HIV-negative donors. The goal is to investigate the potential role of these milk cells as...
- This federal Project Grant award for $711,993.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to examine the effects of Mycobacterium tuberculosis (MTB) disease on HIV-1 pathogenesis in people living with HIV (PWH). The research aims to assess how MTB disease influences the development of broadly neutralizing HIV-1 antibodies, the emergence of NAb-resistant viral...